Other Events ·
On July 20, 2026, Silexion Therapeutics Corp shareholders approved two proposals at a reconvened extraordinary general…
SLXNSilexion Therapeutics Corp
On July 20, 2026, Silexion Therapeutics Corp shareholders approved two proposals at a reconvened extraordinary general meeting. First, the company increased its authorized share capital by 10,000,000 ordinary shares, raising the total from 5,900,000 to 15,900,000 shares with a par value of $0.135 each. Second, shareholders approved the exercisability of 399,020 Series C and D ordinary warrants at $5.00 per share and 13,966 placement agent warrants at $6.25 per share, both stemming from a May 18, 2026 transaction. The memorandum amendment became effective on July 21, 2026. Silexion Therapeutics Corp is a biotechnology company that develops therapeutic treatments.